Please login to the form below

Not currently logged in
Email:
Password:

New US head for Daiichi Sankyo

Glenn Gormley replaces John Gargiulo who steps down as president and CEO

Daiichi Sankyo Glenn Gormley Daiichi Sankyo has announced a shake-up of its senior leadership team in the US.

John Gargiulo well step down as president and CEO of the group's US subsidiary Daiichi Sankyo Inc to be replaced by Dr Glenn Gormley, who takes on the role of president and chairman.

Dr Gormley (pictured right) will also continue in his existing roles as president, Daiichi Sankyo pharma development; global head of R&D; and senior executive officer.

In addition to the announcement that Gargiulo is to step down as president and CEO, he will also leave his role as head of Daiichi's commercial division. He is succeeded there by Greg Barrett, who now holds the title of acting president, Daiichi Sankyo administrative and commercial operations.

The move is a step up for Barrett, who most recently held the position of VP, marketing and managed markets in the US.

No reason was given for the departure of Gargiulo who has been with the company in the US since 1996.

8th October 2013

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...

Infographics